There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Phathom Pharmaceuticals (PHAT – Research Report), Cardiff Oncology (CRDF – Research Report) and Streamline Health Solutions (STRM – Research Report) with bullish sentiments.
Phathom Pharmaceuticals (PHAT)
Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Phathom Pharmaceuticals today. The company’s shares closed last Tuesday at $10.26.
According to TipRanks.com, Knickerbocker is a 4-star analyst with an average return of
Currently, the analyst consensus on Phathom Pharmaceuticals is a Strong Buy with an average price target of $27.50.
See Insiders’ Hot Stocks on TipRanks >>
Cardiff Oncology (CRDF)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cardiff Oncology today and set a price target of $12.00. The company’s shares closed last Tuesday at $1.62.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of
Cardiff Oncology has an analyst consensus of Strong Buy, with a price target consensus of $7.33, which is a 366.9% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $5.00 price target.
Streamline Health Solutions (STRM)
Craig-Hallum analyst Matt Hewitt assigned a Buy rating to Streamline Health Solutions today. The company’s shares closed last Tuesday at $0.79, close to its 52-week low of $0.68.
According to TipRanks.com, Hewitt is a 1-star analyst with an average return of
Streamline Health Solutions has an analyst consensus of Moderate Buy, with a price target consensus of $2.00, which is a 153.1% upside from current levels. In a report issued on September 18, Lake Street also maintained a Buy rating on the stock with a $2.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PHAT:
- Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
- Phathom announces submission of six-month stability data for GERD NDA
- Phathom Pharmaceuticals reports Q2 EPS (84c), consensus ($1.00)
